Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Wednesday that the U.S. FDA has accepted its resubmitted Biologics License ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Three consecutive commercial-scale drug product batches successfully produced ...

Telix Pharmaceuticals (TLX) stock in focus as company secures FDA priority review for TLX250-CDx, a PET imaging agent for ...

If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common ...

After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for ...

Shoals is highly profitable and generates significant operating cash flow relative to its debt balance, further supporting our view that its financial strength is sound. We assign a no-moat rating to ...